Pushan Aggarwal

Dr. Pushan Aggarwal


Research Focus & Metrics

Representative Publications

View All Publications
11 August 2023 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
AKAnjay Khandelwal
Anjay Khandelwal
MSMatthew Satariano
Matthew Satariano
KDKush Doshi
Kush Doshi
PAPushan Aggarwal
Pushan Aggarwal
VAVardhan Avasarala
Vardhan Avasarala
RRRupesh Raina
Rupesh Raina
Acute kidney injury (AKI), a common and severe complication following burn injuries, presents a significant challenge due to its broad clinical manifestations and diverse etiologies. AKI, previously known as acute renal failure, can present abruptly following burns or thermal injuries, causing detrimental health outcomes such as progressive kidney dysfunction, increased hospital length of stay, and requirement of renal replacement therapy (RRT). AKI affects the maintenance of homeostasis of fluid and electrolytes, elimination of metabolic wastes and byproducts, and acid–base balance. Aggressive nutritional support is particularly necessitated in burn patients to prevent protein-energy wasting and a negative nitrogen balance. Understanding the pathogenesis of AKI in burns and improving its prevention and early diagnosis are active areas of research in this field. Despite the potential benefits, the optimal timing and threshold for RRT initiation in burn patients with AKI remain unclear, warranting further studies. Ongoing investigations focus on refining RRT techniques, evaluating biomarkers for early detection of AKI, and exploring adjunctive therapies to enhance renal recovery. The aim of this study is to review the etiology, diagnostic tools, and interventions that improve outcomes associated with AKI in burn-related settings.

23 September 2026 in JACC: Case Reports
Verified
Journal Article
Open access
PAPushan Aggarwal
Pushan Aggarwal
CACraig Alpert
Craig Alpert
DDDaniel Davies
Daniel Davies

9 May 2026 in International Journal of Cardiology Cardiovascular Risk and Prevention
Verified
Journal Article
Open access
PAPushan Aggarwal
Pushan Aggarwal
SDSierra Derti
Sierra Derti
AYAishwarya Yannamani
Aishwarya Yannamani
JNJacalyn S. Newman
Jacalyn S. Newman
RTRitika Tuli
Ritika Tuli
HKHayah Kassis-George
Hayah Kassis-George
Hypertensive disorders of pregnancy (HDP) are established precursors to future cardiovascular disease. Current guidelines endorse labetalol, nifedipine, and methyldopa as first-line antihypertensive therapies, but data on long-term maternal cardiovascular risk are limited. We evaluated five-year postpartum outcomes of HDP patients who were exposed to nifedipine or labetalol during pregnancy. We conducted a retrospective cohort study using the TriNetX US Collaborative Network. Patients were identified using ICD-10-CM codes for HDP—excluding those with pre-existing hypertension-and categorized by treatment with labetalol or nifedipine. Patients exposed to amlodipine or methyldopa were excluded. After 1:1 propensity score matching, we compared cardiovascular and renal outcomes over five years. Results are reported as adjusted odds ratios (aOR) with 95% confidence intervals (CI) and as hazard ratios (HR) from Kaplan-Meier survival analysis. After matching, 11,764 patients remained in each cohort (23,528 total). Nifedipine exposure was associated with lower odds of chronic hypertension (CH, aOR 0.835, 95% CI [0.778, 0.896], p < 0.001), heart failure (HF, aOR 0.699, 95% CI [0.527, 0.926], p = 0.012), HF with reduced ejection fraction (HFrEF, aOR 0.608, 95% CI [0.418, 0.886], p = 0.009), and chronic kidney disease (CKD, aOR 0.653, 95% CI [0.492, 0.867], p = 0.003) compared to labetalol. Time-to-event analysis confirmed these findings. Among HDP patients, nifedipine exposure during the index pregnancy was associated with lower five-year risks of CH, HF, HFrEF, and CKD compared with labetalol. These findings suggest that antihypertensive choice in pregnancy may differentially affect long-term maternal cardiovascular health.

14 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JJJyoti Jain
Jyoti Jain
RKRahul Karna
Rahul Karna
TMTanveer Ud Din Mian
Tanveer Ud Din Mian
ANAdeel Nasrullah
Adeel Nasrullah
PAPalash Asawa
Palash Asawa
KKKassis-George Kassis-George
Kassis-George Kassis-George
Obesity and pulmonary hypertension (PH) frequently coexist, but obesity is not a distinct PH group. This narrative review of the literature published through 27 September 2026 appraises the evidence by PH group. Obesity is most clearly linked to PH through intermediate conditions, particularly heart failure with preserved ejection fraction, obstructive sleep apnea, and obesity hypoventilation syndrome, and it can complicate hemodynamic classification because elevated intrathoracic pressure may raise the measured pulmonary arterial wedge pressure. Experimental studies suggest direct pulmonary vascular effects through adipokine imbalance, inflammation, altered estrogen metabolism, oxidative stress, and insulin resistance; however, an independent causal role of obesity in human pulmonary arterial hypertension has not been established. Small, mostly observational studies report lower estimated pulmonary pressures after bariatric surgery, but a benefit of intentional weight loss on invasive hemodynamics or clinical PH outcomes is unproven. Incretin-based therapies produce substantial weight loss and improve symptoms in obesity-related heart failure with preserved ejection fraction; acute human hemodynamic data are emerging, but long-term efficacy in PH has not been tested. Higher body mass index has been associated with lower observed mortality in several PH cohorts, possibly reflecting confounding and reverse causation. We distinguish established findings from hypotheses and highlight research priorities.

26 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
PAPushan Aggarwal
Pushan Aggarwal
AYAishwarya Yannamani
Aishwarya Yannamani
JJJyoti Jain
Jyoti Jain
IKIlija Klipa
Ilija Klipa
AOAndrew Oehler
Andrew Oehler
KKKassis-George Kassis-George
Kassis-George Kassis-George
Cardiac rehabilitation (CR) is a multicomponent secondary prevention intervention that improves functional capacity and quality of life across cardiac diagnoses, yet remains markedly underused in heart failure (HF). Existing reviews treat efficacy, coverage, delivery, and equity separately; this narrative review integrates them to clarify why uptake in HF remains low despite an established evidence base. We searched PubMed/MEDLINE and the Cochrane Library from January 2009 through December 2025, prioritizing clinical practice guidelines, landmark trials, systematic reviews, registry analyses, and U.S. policy documents, with narrative synthesis across efficacy, coverage, delivery, and equity. In heart failure with reduced ejection fraction (HFrEF), exercise-based CR consistently improves peak oxygen consumption by roughly 15 to 17 percent, improves health status, and reduces short-term all-cause hospitalization. In heart failure with preserved ejection fraction (HFpEF), supervised exercise improves functional capacity and quality of life, but a large pragmatic outcome trial and Medicare coverage remain lacking. In appropriately selected, clinically stable patients, hybrid and virtual delivery produce comparable short-term functional and quality-of-life gains, with more limited direct evidence for hard clinical endpoints. Closing the HFpEF coverage gap, automating HFrEF referral, diversifying delivery, and embedding equity across the CR pipeline are actionable priorities for realizing CR’s potential in HF.